Intech Investment Management LLC Makes New $93,000 Investment in Ocugen, Inc. (NASDAQ:OCGN)

Intech Investment Management LLC acquired a new stake in Ocugen, Inc. (NASDAQ:OCGN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 93,673 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors and hedge funds have also modified their holdings of OCGN. GSA Capital Partners LLP purchased a new stake in Ocugen in the 3rd quarter worth approximately $203,000. NorthCrest Asset Manangement LLC acquired a new stake in shares of Ocugen during the third quarter worth $90,000. SG Americas Securities LLC purchased a new stake in shares of Ocugen in the third quarter valued at $87,000. The Manufacturers Life Insurance Company acquired a new position in Ocugen in the second quarter valued at $166,000. Finally, Xponance Inc. purchased a new position in Ocugen during the second quarter worth about $25,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on OCGN. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Ocugen in a report on Monday, November 18th. Maxim Group started coverage on shares of Ocugen in a report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Ocugen in a research report on Monday, November 11th.

Ocugen Price Performance

OCGN stock opened at $0.87 on Monday. The company has a market cap of $253.45 million, a PE ratio of -4.83 and a beta of 3.82. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $0.95 and a two-hundred day moving average price of $1.26. Ocugen, Inc. has a 12-month low of $0.36 and a 12-month high of $2.11.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.